NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

2272.00 79.80 (3.64%)

26.74% Gain from 52W Low

328.9K NSE+BSE Volume

NSE 09 Oct, 2026 1:17 PM (IST)

64,121.5

Market Cap

High in industry

Beta 1Year

Low volatility

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Search Inside the pdf :

Glenmark Pharmaceuticals Ltd.

07 Aug 2026

2272.00

3.64%

Outlook

Accumulate: Glenmark Pharmaceuticals Ltd.

Target

Deven Choksey

Glenmark Pharmaceuticals' outlook remains constructive, supported by sustained outperformance in the India formulations business, improving growth in North America driven by new respiratory and limited-competition generic launches, and the commencement of oncology product commercialization from H2 FY27.

Glenmark Pharmaceuti.. has an average target of 2434.50 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

04 Aug 2026

2272.00

3.64%

Growth accelerates across regions; profitability yet to catch up

Hold: Glenmark Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Glenmark Pharmaceuticals (Glenmark)’s Q1FY27 revenue was better our estimates, although EBITDA and profits lagged expectations. Strong growth across India (+15.5% YoY), US (+8.5% YoY) and emerging markets (+27.7% YoY) drove the revenue outperformance.

Glenmark Pharmaceuti.. has an average target of 2434.50 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

03 Aug 2026

2272.00

3.64%

India and US lead the recovery

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) delivered in-line revenue for 1QFY27. However, it delivered a 7% and 10% miss on EBITDA and PAT for the quarter, respectively.

Glenmark Pharmaceuticals Ltd. is trading above its 200 day SMA of 2206.4

Glenmark Pharmaceuticals Ltd.

09 Jul 2026, 12:00AM

2272.00

3.64%

Glenmark Pharmaceuticals Ltd. – Q1FY27 Preview:

Accumulate: Glenmark Pharmaceuticals Ltd.

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 16.8% / 86.1% / 111.8% for the period of FY26-FY28.

Number of FII/FPI investors increased from 436 to 473 in Jun 2026 qtr.

Glenmark Pharmaceuticals Ltd.

01 Jul 2026

2272.00

3.64%

GLENMARK PHARMACEUTICALS

Accumulate: Glenmark Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

*over or under performance to benchmark index Glenmark Pharmaceuticals Ltd, which has a presence in over 80 countries, focuses on the generics, specialty and over-the-counter (OTC) segments, with a strong presence in diabetes, cardiovascular and oral contraceptives. In Q4FY26, Glenmark's normalized revenue grew 11.1% YoY to Rs. 3,616cr, driven...

Number of FII/FPI investors increased from 436 to 473 in Jun 2026 qtr.

Glenmark Pharmaceuticals Ltd.

10 Jun 2026

2272.00

3.64%

Innovation Business Can Become a Major Value Driver

Accumulate: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Outlook remains positive, supported by multiple growth drivers across its innovation, specialty, and US generics businesses. Continued scaling of Ryaltris, commercialization of new respiratory products in the US, and the restart of injectable operations are expected to support earnings growth over the next few years.

Glenmark Pharmaceuti.. has an average target of 2434.50 from 4 brokers.

Glenmark Pharmaceuticals Ltd.

01 Jun 2026

2272.00

3.64%

A mixed quarter; US/DF underperforms for the quarter

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) delivered lower-than-expected financial performance for the quarter. While revenue was in line with our estimate, EBITDA was a 7% miss.

Number of FII/FPI investors increased from 436 to 473 in Jun 2026 qtr.

Glenmark Pharmaceuticals Ltd.

03 Feb 2026

2272.00

3.64%

Sustainability of cost curbs key to boost earnings growth

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark’s Q3FY26 revenue growth was led by India biz, while US growth was muted post adjusted for USD 18mn of milestone income. Gross margin was lower by 259bps YoY due to unfavourable product and geographical mix, though cost curbs drove 131bps expansion in EBITDA margin.

Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2409.0

Glenmark Pharmaceuticals Ltd.

02 Feb 2026

2272.00

3.64%

Mixed quarter; domestic strengthens

Buy: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Glenmark Pharma (GNP) posted largely in-line financial performance in 3QFY26. The quarterly performance was driven by a healthy revival in the domestic formulation (DF) business, out-licensing income related to ISB2001, and better performance in emerging markets.

Glenmark Pharmaceuticals Ltd.'s price crossed above 200Day SMA today

Is Glenmark Pharmaceuticals Ltd. worth buying?

581 Votes:

Buy 79.52%

Sell 13.6%

Hold 6.88%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf